AC
WINT

Armistice Capital’s Windtree Therapeutics WINT Stock Holding History

Armistice Capital’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,140
Closed -$375K – 304
2024
Q3 		$375K Buy
+3,140
New +$948K 0.01% 198

Other funds holding WINT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Armistice Capital's WINT Position: Q4 2024 in Review

Armistice Capital sold out of Windtree Therapeutics (WINT) in Q4 2024, closing a stake of 3,140 shares — an estimated $375K sold.

Armistice Capital first reported a position in WINT in Q3 2024 and held it in 1 quarter. The position peaked at $375K in Q3 2024. 11 funds tracked by Wall St. Rank hold WINT as of Q4 2024.

  • Armistice Capital reported no remaining Windtree Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Armistice Capital sold 3,140 Windtree Therapeutics shares in Q4 2024, an estimated $375K.
  • Armistice Capital first reported a position in Windtree Therapeutics in Q3 2024 and held it in 1 quarter.
  • Armistice Capital's Windtree Therapeutics position peaked at $375K in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.